Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma
Purpose The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2009-02, Vol.63 (3), p.459-467 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 467 |
|---|---|
| container_issue | 3 |
| container_start_page | 459 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 63 |
| creator | Shim, Ju Hyun Park, Joong-Won Nam, Byung Ho Lee, Woo Jin Kim, Chang-Min |
| description | Purpose The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007. Results One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb. The overall response rate was 19.7%, and 45.0% achieved tumor growth control. Tumor response and disease stability were significantly higher in patients with serum α-FP < 400 ng/mL, those with CLIP score |
| doi_str_mv | 10.1007/s00280-008-0759-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2694743136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2694743136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-1322082aa0577bdbe943b047b96f4e8a58a14db65af521ea3f95588e1e91b9173</originalsourceid><addsrcrecordid>eNp9kV-L1DAUxYMo7uzoB_BFi-Jj9d78maSPsqyrsOCD7nNIMzc7XdqmJi3ugB_eLB3cJ4VAAud3zr3kMPYK4QMC6I8ZgBuoAUwNWjX1_RO2QSl4DUaKp2wDQspaaZBn7DznOwCQKMRzdoZF18LIDft9GULnnT9WMVQ-Dm03urmLY-UPNMT5QMlNx-pXNx8q7yby3ewKQtXUL7nyXZ76go9VOVN50DjnFV7GRJl8oXuqDlTE6Knvl96lEpR8N8bBvWDPguszvTzdW3bz-fLHxZf6-tvV14tP17WXCucaBedguHOgtG73LTVStCB12-yCJOOUcSj37U65oDiSE6FRyhhCarBtUIste7fmTin-XCjP9i4uaSwjLd81UkuBYleot_-kUEgDvIBbhivkU8w5UbBT6gaXjhbBPpRi11JsKcU-lGLvi-f1KXhpB9o_Ok4tFOD9CXDZuz4kN5av_ctxBDTQQOH4yuUijbeUHjf83_Q3qym4aN1tKsE33zmgAFRa4g7EH3uhr1I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213480274</pqid></control><display><type>article</type><title>Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Shim, Ju Hyun ; Park, Joong-Won ; Nam, Byung Ho ; Lee, Woo Jin ; Kim, Chang-Min</creator><creatorcontrib>Shim, Ju Hyun ; Park, Joong-Won ; Nam, Byung Ho ; Lee, Woo Jin ; Kim, Chang-Min</creatorcontrib><description>Purpose The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007. Results One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb. The overall response rate was 19.7%, and 45.0% achieved tumor growth control. Tumor response and disease stability were significantly higher in patients with serum α-FP < 400 ng/mL, those with CLIP score <= 2, and those with a uninodular intrahepatic tumor or no residual intrahepatic tumor with extrahepatic tumors alone (P < 0.05). The median time to progression (TTP) and median overall survival were 2.8 months (95% CI 2.5-3.1 months) and 10.5 months (95% CI 7.9-13.1 months), respectively. Multivariate analyses showed that a uninodular or no residual intrahepatic tumor (hazard ratio, 0.524; P = 0.006) and female gender (hazard ratio, 0.539; P = 0.019) were independent predictors affecting TTP. Gastrointestinal symptoms were the most common grade 3 and 4 toxicities. Conclusions Although XP chemotherapy produced moderate survival outcomes in advanced HCC patients, it was efficacious in the treatment of HCC patients with a uninodular or no residual intrahepatic tumor, especially women, regardless of extrahepatic tumor status.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-008-0759-x</identifier><identifier>PMID: 18437384</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject><![CDATA[Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer ; Cancer Research ; Capecitabine ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; Chemotherapy ; Cisplatin ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastrointestinal symptoms ; Health hazards ; Hepatocellular carcinoma ; hepatoma ; Humans ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; mortality ; Oncology ; Original Article ; Patients ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Response ; Survival ; Survival Analysis ; Time to progression ; Toxicity ; Tumors]]></subject><ispartof>Cancer chemotherapy and pharmacology, 2009-02, Vol.63 (3), p.459-467</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2008.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-1322082aa0577bdbe943b047b96f4e8a58a14db65af521ea3f95588e1e91b9173</citedby><cites>FETCH-LOGICAL-c451t-1322082aa0577bdbe943b047b96f4e8a58a14db65af521ea3f95588e1e91b9173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-008-0759-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-008-0759-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21018090$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18437384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shim, Ju Hyun</creatorcontrib><creatorcontrib>Park, Joong-Won</creatorcontrib><creatorcontrib>Nam, Byung Ho</creatorcontrib><creatorcontrib>Lee, Woo Jin</creatorcontrib><creatorcontrib>Kim, Chang-Min</creatorcontrib><title>Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007. Results One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb. The overall response rate was 19.7%, and 45.0% achieved tumor growth control. Tumor response and disease stability were significantly higher in patients with serum α-FP < 400 ng/mL, those with CLIP score <= 2, and those with a uninodular intrahepatic tumor or no residual intrahepatic tumor with extrahepatic tumors alone (P < 0.05). The median time to progression (TTP) and median overall survival were 2.8 months (95% CI 2.5-3.1 months) and 10.5 months (95% CI 7.9-13.1 months), respectively. Multivariate analyses showed that a uninodular or no residual intrahepatic tumor (hazard ratio, 0.524; P = 0.006) and female gender (hazard ratio, 0.539; P = 0.019) were independent predictors affecting TTP. Gastrointestinal symptoms were the most common grade 3 and 4 toxicities. Conclusions Although XP chemotherapy produced moderate survival outcomes in advanced HCC patients, it was efficacious in the treatment of HCC patients with a uninodular or no residual intrahepatic tumor, especially women, regardless of extrahepatic tumor status.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Capecitabine</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastrointestinal symptoms</subject><subject>Health hazards</subject><subject>Hepatocellular carcinoma</subject><subject>hepatoma</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>mortality</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Response</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Time to progression</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kV-L1DAUxYMo7uzoB_BFi-Jj9d78maSPsqyrsOCD7nNIMzc7XdqmJi3ugB_eLB3cJ4VAAud3zr3kMPYK4QMC6I8ZgBuoAUwNWjX1_RO2QSl4DUaKp2wDQspaaZBn7DznOwCQKMRzdoZF18LIDft9GULnnT9WMVQ-Dm03urmLY-UPNMT5QMlNx-pXNx8q7yby3ewKQtXUL7nyXZ76go9VOVN50DjnFV7GRJl8oXuqDlTE6Knvl96lEpR8N8bBvWDPguszvTzdW3bz-fLHxZf6-tvV14tP17WXCucaBedguHOgtG73LTVStCB12-yCJOOUcSj37U65oDiSE6FRyhhCarBtUIste7fmTin-XCjP9i4uaSwjLd81UkuBYleot_-kUEgDvIBbhivkU8w5UbBT6gaXjhbBPpRi11JsKcU-lGLvi-f1KXhpB9o_Ok4tFOD9CXDZuz4kN5av_ctxBDTQQOH4yuUijbeUHjf83_Q3qym4aN1tKsE33zmgAFRa4g7EH3uhr1I</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Shim, Ju Hyun</creator><creator>Park, Joong-Won</creator><creator>Nam, Byung Ho</creator><creator>Lee, Woo Jin</creator><creator>Kim, Chang-Min</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20090201</creationdate><title>Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma</title><author>Shim, Ju Hyun ; Park, Joong-Won ; Nam, Byung Ho ; Lee, Woo Jin ; Kim, Chang-Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-1322082aa0577bdbe943b047b96f4e8a58a14db65af521ea3f95588e1e91b9173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Capecitabine</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastrointestinal symptoms</topic><topic>Health hazards</topic><topic>Hepatocellular carcinoma</topic><topic>hepatoma</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>mortality</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Response</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Time to progression</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shim, Ju Hyun</creatorcontrib><creatorcontrib>Park, Joong-Won</creatorcontrib><creatorcontrib>Nam, Byung Ho</creatorcontrib><creatorcontrib>Lee, Woo Jin</creatorcontrib><creatorcontrib>Kim, Chang-Min</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shim, Ju Hyun</au><au>Park, Joong-Won</au><au>Nam, Byung Ho</au><au>Lee, Woo Jin</au><au>Kim, Chang-Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>63</volume><issue>3</issue><spage>459</spage><epage>467</epage><pages>459-467</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007. Results One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb. The overall response rate was 19.7%, and 45.0% achieved tumor growth control. Tumor response and disease stability were significantly higher in patients with serum α-FP < 400 ng/mL, those with CLIP score <= 2, and those with a uninodular intrahepatic tumor or no residual intrahepatic tumor with extrahepatic tumors alone (P < 0.05). The median time to progression (TTP) and median overall survival were 2.8 months (95% CI 2.5-3.1 months) and 10.5 months (95% CI 7.9-13.1 months), respectively. Multivariate analyses showed that a uninodular or no residual intrahepatic tumor (hazard ratio, 0.524; P = 0.006) and female gender (hazard ratio, 0.539; P = 0.019) were independent predictors affecting TTP. Gastrointestinal symptoms were the most common grade 3 and 4 toxicities. Conclusions Although XP chemotherapy produced moderate survival outcomes in advanced HCC patients, it was efficacious in the treatment of HCC patients with a uninodular or no residual intrahepatic tumor, especially women, regardless of extrahepatic tumor status.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18437384</pmid><doi>10.1007/s00280-008-0759-x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2009-02, Vol.63 (3), p.459-467 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_2694743136 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Cancer Research Capecitabine Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Chemotherapy Cisplatin Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal symptoms Health hazards Hepatocellular carcinoma hepatoma Humans Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Medicine Medicine & Public Health Middle Aged mortality Oncology Original Article Patients Pharmacology. Drug treatments Pharmacology/Toxicology Response Survival Survival Analysis Time to progression Toxicity Tumors |
| title | Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A13%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20combination%20chemotherapy%20with%20capecitabine%20plus%20cisplatin%20in%20patients%20with%20unresectable%20hepatocellular%20carcinoma&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Shim,%20Ju%20Hyun&rft.date=2009-02-01&rft.volume=63&rft.issue=3&rft.spage=459&rft.epage=467&rft.pages=459-467&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-008-0759-x&rft_dat=%3Cproquest_cross%3E2694743136%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213480274&rft_id=info:pmid/18437384&rfr_iscdi=true |